

14 Apr 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide's promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas's chief strategy officer.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 April 2024, including: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide's promise in heart failure; [AstraZeneca PLC](#) looks to multiple cancer modalities; and an interview with [Astellas Pharma, Inc.](#)'s chief strategy officer.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[The Shifting Sands Of Biopharma R&D](#)" - Scrip, 8 Apr, 2024.)

(Also see "[Big Pharma Oncology Strategies Aim To Treat Cancer Earlier](#)" - Scrip, 9 Apr, 2024.)

(Also see "[Semaglutide Might Treat Heart Failure Directly](#)" - Scrip, 8 Apr, 2024.)

(Also see "[AstraZeneca Looks To Many Modalities In Cancer](#)" - Scrip, 8 Apr, 2024.)

(Also see "[Astellas CStO Pearson: We're Not Short Of Opportunities To Compensate For LOEs](#)" - Scrip, 8 Apr, 2024.)

[Click here to explore this interactive content online](#) 